Skip to content
Biodatica
Start free

Tasca Therapeutics Corp

CAMBRIDGE, MA · also filed as None

OncologyFiled/Approved
Compare Sign in to watch

What changed

Phase II trial registered: Clinical Observation of Bupivacaine Liposome for Lower Extremity Nerve Block

2mo agoTrial registeredMay 14, 2026Source filing (opens the source filing in a new tab)

Momentum

92no change

Momentum 92 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

~13months

The last disclosed raise still models out past a year.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

81 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R21 · $457k · non-dilutive

    May 1, 2026

    UT SOUTHWESTERN MEDICAL CENTER · PI CHEN, XIN · NCATS · award ends Apr 30, 2028 · AAV9fyhr gene replacement therapy for PDHA1 deficiency in the E75A mouse model

    NIH RePORTER · NIH RePORTER 11338116 (opens the source filing in a new tab)

  2. Grant

    R21 · $402k · non-dilutive

    May 1, 2026

    UNIVERSITY OF HAWAII AT MANOA · PI CHEN, XIN · NCI · award ends Apr 30, 2028 · Therapeutic Targeting of Upregulated BAP1 in Human Hepatocellular Carcinoma

    NIH RePORTER · NIH RePORTER 11350331 (opens the source filing in a new tab)

  3. Grant

    K99 · $128k · non-dilutive

    Apr 1, 2026

    STANFORD UNIVERSITY · PI CHEN, XIN · NIAID · award ends Mar 31, 2028 · Characterizing autoreactive B cells and their roles in the pathogenesis of SLE using immune organoids

    NIH RePORTER · NIH RePORTER 11282591 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Feb 1, 2026

    Patients Eligible for Elective Lower Extremity Femoral Nerve Surgery, Knee Arthroscopic Surgery · COMPLETED · sponsor: Hainan Medical College · Clinical Observation of Bupivacaine Liposome for Lower Extremity Nerve Block

    ClinicalTrials.gov · NCT07366905 (opens the source filing in a new tab)

  5. Filing

    Form D/A · $48M

    Dec 1, 2025

    Tasca Therapeutics Corp · private raise, self-reported by the issuer

    SEC EDGAR · 0002046762-25-000005 (opens the source filing in a new tab)

  6. Trial

    PHASE4 registered

    Nov 30, 2025

    Laparoscopic Surgery for Cholecystitis · COMPLETED · sponsor: Xin Chen · Clinical Study on the Effect of Tegileridine on Postoperative Pain in Patients Undergoing Abdominal Surgery.

    ClinicalTrials.gov · NCT07277153 (opens the source filing in a new tab)

  7. Grant

    R01 · $664k · non-dilutive

    Apr 1, 2025

    MASSACHUSETTS GENERAL HOSPITAL · PI WU, XU · NCI · award ends Mar 31, 2030 · Novel regulation and functions of TEAD-VGLL complex

    NIH RePORTER · NIH RePORTER 11301030 (opens the source filing in a new tab)

  8. Grant

    UG3 · $200k · non-dilutive

    May 14, 2024

    UNIVERSITY OF HAWAII AT HILO · PI CAO, SHUGENG · NCI · award ends Apr 30, 2027 · Discovery of novel natural TEAD inhibitors for the chemoprevention of liver tumors

    NIH RePORTER · NIH RePORTER 11324226 (opens the source filing in a new tab)

  9. Grant

    R35 · $400k · non-dilutive

    May 1, 2018

    JOHNS HOPKINS UNIVERSITY · PI CHEN, XIN · NIGMS · award ends Apr 30, 2029 · Study epigenetic inheritance during development, homeostasis and regeneration

    NIH RePORTER · NIH RePORTER 11325447 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources